Perrigo (NYSE:PRGO) Releases FY 2026 Earnings Guidance

Perrigo (NYSE:PRGO) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.250-2.550 for the period, compared to the consensus estimate of 2.110. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

Analysts Set New Price Targets

PRGO has been the subject of a number of recent research reports. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research upgraded shares of Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.33.

Perrigo Trading Down 6.2%

Shares of NYSE:PRGO traded down $0.82 on Thursday, hitting $12.45. 1,743,235 shares of the company’s stock were exchanged, compared to its average volume of 3,207,063. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -0.95, a price-to-earnings-growth ratio of 1.29 and a beta of 0.51. Perrigo has a 12 month low of $9.23 and a 12 month high of $24.60. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59. The business’s 50 day simple moving average is $10.56 and its two-hundred day simple moving average is $11.55.

Perrigo (NYSE:PRGO) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.19. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.06) EPS. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts anticipate that Perrigo will post 2.09 EPS for the current fiscal year.

Perrigo Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 28th will be issued a $0.29 dividend. The ex-dividend date is Friday, August 28th. This represents a $1.16 annualized dividend and a dividend yield of 9.3%. Perrigo’s payout ratio is currently -8.85%.

Key Stories Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Perrigo reported second-quarter adjusted earnings of $0.50 per share, beating the $0.31 consensus estimate by $0.19 and marking a return to profitability versus a year-earlier loss. Revenue of approximately $1.02 billion was broadly in line with expectations. Perrigo Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised or updated fiscal 2026 EPS guidance to $2.25-$2.55, above the roughly $2.11 analyst consensus, while reaffirming expectations for a stronger second half. The company maintained revenue guidance of $4.0-$4.2 billion. Perrigo Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Perrigo cited market-share gains in U.S. store-brand over-the-counter products and key European brands. Infant Formula sales increased 23.1%, while the completed Dermacosmetics divestiture is streamlining the portfolio and supporting the company’s debt-reduction strategy. Perrigo Q2 Net Sales Fall 3.2 Percent
• Neutral Sentiment: Management continues strategic reviews of its Infant Formula and Oral Care businesses. Potential portfolio changes could improve focus and finances, but the timing and financial impact remain uncertain. Perrigo Q2 Results Earnings Presentation
• Negative Sentiment: Second-quarter net sales declined about 3.1%-3.2% year over year, and core organic sales fell 3.5%. Perrigo also cited category softness, macroeconomic pressure and substantial leverage, with approximately $3.3 billion of debt versus $400 million in cash. Perrigo Q2 Earnings Snapshot

Institutional Investors Weigh In On Perrigo

A number of hedge funds have recently made changes to their positions in PRGO. Price T Rowe Associates Inc. MD grew its stake in Perrigo by 3.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 17,574,227 shares of the company’s stock valued at $244,634,000 after purchasing an additional 653,925 shares during the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Perrigo by 291.9% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,824,759 shares of the company’s stock worth $108,921,000 after purchasing an additional 5,828,076 shares during the last quarter. State Street Corp lifted its holdings in shares of Perrigo by 9.5% during the 2nd quarter. State Street Corp now owns 7,340,323 shares of the company’s stock valued at $196,134,000 after purchasing an additional 637,678 shares during the last quarter. Invesco Ltd. increased its position in Perrigo by 134.2% during the 4th quarter. Invesco Ltd. now owns 4,542,415 shares of the company’s stock valued at $63,230,000 after buying an additional 2,602,724 shares in the last quarter. Finally, Ion Asset Management Ltd. raised its stake in Perrigo by 34.7% in the second quarter. Ion Asset Management Ltd. now owns 3,817,621 shares of the company’s stock valued at $102,007,000 after buying an additional 983,727 shares during the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.